Cardiovascular effects of selective cyclooxygenase-2 inhibitors (Q35777371)

10 August 2017

1 reference

title

Cardiovascular effects of selective cyclooxygenase-2 inhibitors (English)

1 reference

10 August 2017

Henry Krum

1 reference

10 August 2017

Danny Liew

1 reference

10 August 2017

Juan Aw

1 reference

10 August 2017

Steven Haas

series ordinal

1 reference

10 August 2017

publication date

1 March 2004

1 reference

Expert Review of Cardiovascular Therapy

10 August 2017

published in

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

page(s)

265-270

1 reference

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

The coxibs, selective inhibitors of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Association between naproxen use and protection against acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Pulse pressure, arterial stiffness, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Inflammation in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Selective COX-2 inhibition improves endothelial function in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.265

21 January 2018

Identifiers

DOI

10.1586/14779072.2.2.265

1 reference

10 August 2017

1 reference